Study in Patients With Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00215371|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : November 11, 2010
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: Formoterol Fumarate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Crossover Assignment|
|Study Start Date :||July 2002|
|Primary Completion Date :||October 2002|
|Study Completion Date :||November 2005|
- Primary: The primary efficacy outcome is measure of lung function.
- Secondary: Change in lung function will be examined as a secondary efficacy outcome, as well as vital signs, physical examination, adverse event reporting,etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00215371
|United States, California|
|Long Beach, California, United States, 90806|
|United States, Oregon|
|Medford, Oregon, United States, 97504|